ESSENTIAL MEDICINES IN HUNGARY Arete-Zoe, LLC Date: July 22, 2017 Data lock point: April 28,

"We have essentially been avoiding this elephant in the room for the past twenty years, never daring to state what we know: namely that the use of public healthcare services does not reflect the needs of society, but rather the interests of the institutional system." Dr. Zoltán Ónodi-Szűcs, Hungarian Secretary of State for Health (Haynes, 2017)

System organ classWHO EML WHO EML Available WHO EML Unavailable WHO EML Unavailable % NL EML Both EM Lists (overlap) A – Alimentary tract and metabolic diseases %3813 B – Blood and blood-forming organs %52 C – Cardiovascular system %8113 D – Dermatologicals %143 G - Genito-urinary system, sex hormones %324 H – Hormones, excl. sex hormones and insulins 11 00%63 J – Systemic anti-infectives %2919 L – Anti-neoplastic agents, immunomodulants %177 M – Musculoskeletal system64233%181 N – Nervous system373525%6211 P – Anti-parasitics, insecticides, repellents %00 R – Respiratory system107330%244 S – Sensory organs137646%182 V - Various %21 TOTAL % FIG. 1 - Summary (table): Availability of essential medicines by organ class

FIG. 2 – Summary (graph): Essential medicines lists by organ class WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 3 – Summary (graph): Availability of essential medicines lists by organ class

ALIMENTARY TRACT AND METABOLISM (A)

FIG. 4 – Summary (graph): Availability of registered products (A) – WHO EM List WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 5 – Summary (graph): Availability of registered products (A) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 6 – Summary (graph): Availability of registered products (A) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG 7 – Stomatologicals (A01) and Acid related disorders (A02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 8 – Drugs for functional GIT disorders (A03), antiemetics and antinauseants (A04) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 9 – Bile and liver therapy (A05), drugs for constipation (A06), anti-diarrheals (A07) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 10 – Anti-obesity drugs (A08) and digestives incl. enzymes (A09) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 11 – Drugs used in diabetes (A10) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Vitamins (A11) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Mineral supplements (A12), other alimentary tract & metabolism drugs (A16) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

Unavailable WHO EML ATC CodeActive ingredient A04AD01hyoscine hydrobromide A06AA02docusate sodium A07AA6paromomycin A07EA02hydrocortisone A11CC01 ergocalciferol A11HA01 nicotinamide A11HA04 riboflavin A12CD01 sodium fluoride

BLOOD AND BLOOD- FORMING ORGANS (B)

FIG. 14 – Summary (graph): Availability of registered products (B) – WHO EM List and National EM List combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG 15 - Anti-thrombotic agents (B01) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG 16 – Anti-hemorrhagics (B02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG 17 – Anti-anemic preparations (B03) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG 18 – Blood substitutes and perfusion solutions (B05) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

Unavailable WHO EML ATC CodeActive ingredient B05AX01red blood cells B05AX03fresh frozen plasma B05XA05magnesium sulfate

CARDIOVASCULAR SYSTEM (C)

FIG. 20A – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 20B – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG 19 – Summary (graph): Availability of registered products (C) – WHO EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 20C – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 20D – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 21A – Summary (graph): Availability of registered products (C) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 21B – Summary (graph): Availability of registered products (C) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 21C – Summary (graph): Availability of registered products (C) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Cardiac therapy (C01) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Antihypertensives (C02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 24 – Diuretics (C03) and peripheral vasodilatators (C04) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 25 – Vasoprotectives (C05) and beta-blocking agents (C07) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Calcium-channel blockers (C08) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Renin-angiotensin system: ACE inhibitors (C09A) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Renin-angiotensin system: ACE inhibitors in combinations (C09B) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Renin-angiotensin system: Angiotensin II antagonists (C09C) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Renin-angiotensin system: Angiotensin II antagonists in combinations (C09D) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Lipid modifying agents (C10) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

Unavailable WHO EML ATC CodeActive ingredient C01CA26ephedrine C01DA08isosorbide dinitrate C02DB02hydrazaline C02DD01nitroprusside C03DB01amiloride

DERMATOLOGICALS (D)

FIG. 32 – Summary (graph): Availability of registered products (D) – WHO EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 33 – Summary (graph): Availability of registered products (D) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 34 – Summary (graph): Availability of registered products (D) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Antifungals for dermatological use (D01) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Emollients and protectives (D02), antipsoriatics (D05) and antibiotics and chemotherapeutics for dermatological use (D06) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 37 – Corticosteroids for dermatological use (D07) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 38 – Antiseptics and disinfectants (D08) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 39 – Anti-acne preparations (D10) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

Unavailable WHO EML ATC CodeActive ingredient D01AA01nystatin D01AC02miconazole D01AE12salicylic acid D01AE13selenium sulfide D01BA01griseofulvin D08AC02chlorhexidine D08AE05chloroxylenol D08AX05isopropanol D08AX06potassium permanganate D08AX08ethanol

GENITO-URINARY SYSTEM AND SEX HORMONES (G)

FIG. 40 – Summary (graph): Availability of registered products (G) – WHO EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 41 – Summary (graph): Availability of registered products (G) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 42 – Summary (graph): Availability of registered products (G) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Antiinfectives and antiseptics (G01), other gynecologicals (G02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 44 – Hormonal contraceptives for systemic use: Progestogens and estrogens, fixed combinations (G03AA) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 45 – Hormonal contraceptives for systemic use: Progestogens and estrogens, sequential preparations (G03AB) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 46 –Progestogens (G03AC) and emergency contraceptives (G03AD) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 47 – Androgens (G03B), estrogens (G03C), progestogens (G03D) androgens and female hormones comb. (G03E), and progestogens and estrogens comb. (G03F) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 48 – Gonadotropins and other ovulation stimulants (G03G), antiandrogens (G03H) and other sex hormones and modulators of the genital system (G03X) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 49 – Urologicals (G04) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

Unavailable WHO EML ATC CodeActive ingredient G02AB03ergometrine G02BA02plastic IUD with copper G02BA03plastic IUD with progesteron G03AA05norethisterone and ethinylestradiol G03AA08medroxyprogesterone and estrogen G03AC01norethisterone G03AC03levonorgestrel G03AC08etonorgestrel

HORMONES FOR SYSTEMIC USE, EXCL. SEX HORMONES AND INSULINS (H)

FIG. 50 – Summary (graph): Availability of registered products (H) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 51 – Pituitary and hypothalamic hormones and analogues (H01), corticosteroids for systemic use (H02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 52 – Thyroid therapy (H03), pancreatic hormones (H04), calcium homeostasis (H05) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

ANTIINFECTIVES FOR SYSTEMIC USE (J)

FIG. 53 – Summary (graph): Availability of registered products (J) – WHO EML (values <4 included in table 56C) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 54 – Summary (graph): Availability of registered products (J) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 55A – Summary (graph): Availability of registered products (J) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 55B – Summary (graph): Availability of registered products (J) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG. 55C – Summary (table): Availability of registered products (J) – WHO EML and National EML combined (1-3 registrations) lymecyclineTyphoid vaccines ampicillinpapillomavirus (human types 16, 18) sulfamethoxazole + trimethoprimbenzylpenicillin gentamicinprocain benzylpenicilin amikacincefazolin metronidazoleerythromycin saquinavir (SQV)nitrofurantoin lamivudine + zidovudine (ZDV or AZT)isoniazid meningococcal vaccinesethambutol pneumococcus, purified polysaccharides Agbedaquiline Poliomyelitis vaccinedelamanid Rota virus diarrhea vaccinessimeprevir Varicella zoster vaccinesefavirenz + emtricitabine + tenofovir fosfomycin sofosbuvir ketoconazole dasabuvir p-aminosalicylic acidledipasvir + sofosbuvir rifampicinCholera vaccines pyrazinamidanti-D immunoglobulin rifampicin and isoniazidtetanus immunoglobulin abacavir (ABC)tetanus toxoid daclatasvirhemophilus influenzae B, purified antigen conjugated tuberculosis, live attenuated encephalitis, Japanese, inactivated, whole virus Yellow fever vaccines

FIG. 55D – Summary (table): Availability of registered products (J) – WHO EML and National EML combined (Not available) chloramphenicolclofazimine benzathin benzylpenicilindapsone cloxacillinlopinavir + ritonavir (LPV/r) cefalexinzidovudine (ZDV or AZT) trimethoprimentecavir sulfadiazinelamivudine + nevirapine + zidovudin streptomycinlamivudine + nevirapine + stavudine kanamycinombitasvir + paritaprevir + ritonavir spectinomycindiphtheria antitoxin flucytosinesnake venom antiserum cycloserinerabies immunoglobulin rifabutindiphtheria toxoid rifapentinepertussis vaccine capreomycinmeasles vaccine, live attenuated protionamidemumps vaccine, live attenuated ethionamideRubella vaccines terizidone ethambutol and isoniazid rifampicin, pyrazinamide and isoniazid rifampicin, pyrazinamide, ethambutol and isoniazid

FIG Antibacterials (J01): Tetracyclines (J01A) amphenicols (J01B) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

FIG Antibacterials (J01): Beta-lactams – penicillins (J01C)

FIG Antibacterials (J01): Beta-lactams – non-penicilline (J01D)

FIG Antibacterials (J01): Sulphonamides and trimethoprim (J01E) and macrolides, linkosamides and streptogramins (J01F)

FIG Antibacterials (J01): Aminoglycosides (J01G)

FIG Antibacterials (J01): Quinolones (J01M)

FIG Antibacterials (J01): Other antibacterials (J01X)

FIG. 63 – Antimycotics for systemic use (J02)

FIG. 64A – Antimycobacterials (J04): Tuberculosis (J04A)

FIG. 64B – Antimycobacterials (J04) Tuberculosis (J04A) and leprosy (J04B)

FIG. 65 – Antivirals for systemic use (J05): Nucleosides and nucleotides excl. reverse transcriptase inhibitors (J05AB) and Protease inhibitors (J05AE)

FIG. 66 – Antivirals for systemic use (J05): Nucleoside and nucleotide reverse transcriptase inhibitors (J05AF), Non-nucleoside reverse transcriptase inhibitors (J05G) and Neuraminidase inhibitors (J05AH)

FIG. 67 – Antivirals for systemic use (J05): Antivirals for treatment of HIV infections, combinations (J05AR) and Other antivirals (J05AX)

FIG. 68 – Immune sera and immunoglobulins (J06)

FIG. 69A – Vaccines (J07): Bacterial vaccines (J07A)

FIG. 69B – Vaccines (J07): Bacterial vaccines (J07A)

FIG. 70A – Vaccines (J07): Viral vaccines (J07B)

FIG. 70B– Vaccines (J07): Viral vaccines (J07B)

FIG. 70C– Vaccines (J07): Viral vaccines (J07B)

FIG. 71 – Vaccines (J07): Bacterial and viral vaccines combined (J07C)

Unavailable WHO EML ATC CodeActive ingredient Antibacterials J01BA01chloramphenicol J01CE08benzathin benzylpenicilin J01CF02cloxacillin J01DB01cefalexin J01EA01trimethoprim J01EC02sulfadiazine J01GA01streptomycin J01GB04kanamycin J01XX04spectinomycin Antimycotics J02AX01flucytosine

Unavailable WHO EML Antimycobacterials J04AB01cycloserine J04AB04rifabutin J04AB05rifapentine J04AB30capreomycin J04AD01protionamide J04AD03ethionamide J04AK03terizidone J04AM03ethambutol and isoniazid J04AM05rifampicin, pyrazinamide and isoniazid J04AM06rifampicin, pyrazinamide, ethambutol and isoniazid J04BA01clofazimine J04BA02dapsone

Unavailable WHO EML Antivirals J05AE30lopinavir + ritonavir (LPV/r) J05AF01zidovudine (ZDV or AZT) J05AF10entecavir J05AR05lamivudine + nevirapine + zidovudin J05AR07lamivudine + nevirapine + stavudine J05AX66ombitasvir + paritaprevir + ritonavir Immune sera and immuoglobulins J06AA01diphtheria antitoxin J06AA03snake venom antiserum J06BB05rabies immunoglobulin

Unavailable WHO EML ATC CodeActive ingredient Vaccines J07AF01diphtheria toxoid J07AJ01pertussis vaccine J07BD01measles vaccine, live attenuated J07BE01mumps vaccine, live attenuated J07BJRubella vaccines

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS (L)

FIG. 72A – Summary (graph): Availability of registered products (L) – WHO EML

FIG. 72B – Summary (graph): Availability of registered products (L) – WHO EML

FIG. 73 – Summary (graph): Availability of registered products (L) – National EML

FIG. 74A – Summary (graph): Availability of registered products (L) – WHO EML and National EML combined

FIG. 74B – Summary (graph): Availability of registered products (L) – WHO EML and National EML combined

FIG. 74C – Summary (graph): Availability of registered products (L) – WHO EML and National EML combined

FIG Antineoplastic agents (L01): Alkylating agents (L01A)

FIG Antineoplastic agents (L01): Antimetabolites (L01B)

FIG Antineoplastic agents (L01): Plant alkaloids and other natural products (L01C)

FIG Antineoplastic agents (L01): Cytotoxic antibiotics & related substances (L01D)

FIG Antineoplastic agents (L01): Other antineoplastic agents (L01X)

FIG. 80 – Endocrine therapy (L02)

FIG. 81 – Immunostimulants (L03)

FIG Immunosuppressants (L04)

Unavailable WHO EML ATC CodeActive ingredient L01AA02chlorambucil L01BB03tioguanine L01DA01dactinomycin L01XB01procarbazine L01XX09miltefosine L01XX14tretinoin

MUSCULO-SKELETAL SYSTEM (M)

FIG. 83 – Summary (graph): Availability of registered products (M) – WHO EML

FIG. 84 – Summary (graph): Availability of registered products (M) – National EML

FIG. 85 – Summary (graph): Availability of registered products (M) – WHO EML and National EML combined

FIG. 86 – Musculoskeletal system (M): Anti-inflammatory and anti-rheumatic products (M01)

FIG 87 – Musculoskeletal system (M): Topical products for joint and muscular pain (M02), muscle relaxants (M03)

FIG. 88 – Musculoskeletal system (M): Anti-gout preparations (M04), drugs for the treatment of bone diseases (M05)

Unavailable WHO EML ATC CodeActive ingredient M01CC01penicillamine M03AB01suxamethonium

NERVOUS SYSTEM (N)

FIG. 89A – Summary (graph): Availability of registered products (N) – WHO EML

FIG. 89B – Summary (graph): Availability of registered products (N) – WHO EML

FIG. 90A – Summary (graph): Availability of registered products (N) – National EML

FIG. 90B – Summary (graph): Availability of registered products (N) – National EML

FIG. 90C – Summary (graph): Availability of registered products (N) – National EML

FIG. 91A – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

FIG. 91B – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

FIG. 91C – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

FIG. 91D – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

FIG. 92 – Anesthetics (N01): General anesthetics (N01A)

FIG. 93 – Anesthetics (N01): Local anesthetics (N01B)

FIG. 94 – Analgesics (N02): Opioids (N02A)

FIG. 95 – Analgesics (N02): Other analgesics and antipyretics (N02B) and antimigraine products (N02C)

FIG. 96 – Antiepileptics (N03)

FIG. 97 – Anti-Parkinson drugs (N04)

FIG. 98 – Psycholeptics (N05): Antipsychotics (N05A)

FIG. 99 – Psycholeptics (N05): Anxiolytics (N05B)

FIG. 100 – Psycholeptics (N05): Hyponotics and sedatives (N05C)

FIG. 101 – Psychoanaleptics (N06): Antidepressants (N06A)

FIG. 102 – Psychoanaleptics (N06): Psychostimulants, agents used for ADHD and nootropics (N06B) and anti-dementia drugs (N06D)

FIG. 103 – Other nervous system drugs (N07): Parasympathomimetics (N07A), drugs used in addictive disorders (N07B), anti-vertigo preparations (N07C) and other (N07X)

Unavailable WHO EML ATC CodeActive ingredient N01AB01halotane N03AD01ethosuximide

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS (P)

FIG. 104 – Summary (graph): Availability of registered products (P) – WHO EM List and National EM List combined

FIG. 105 – Antiparasitics, insecticides and repellents (P): Antiprotozoals (P01), anthelmintics (P02) and ectoparasiticides (P03)

FIG. 106 – Antiparasitics, insecticides and repellents (P) – WHO EML unavailable ATC CodeActive ingredient P01AC01diloxanide P01BA02hydroxychloroquine P01BA03primaquine P01BA06amodiaquine P01BB01proguanil P01BC01quinine P01BD01pyrimethamine P01BD51pyrimethamine, comb. P01BE02artemether P01BE03artesunate P01BF01artemether and lumefantrine P01BF02artesunate and mefloquine P01BF03artesunate and amodiaquine P01CA02benznidazole P01CB01meglumine antimoniate ATC CodeActive ingredient P01CB02sodium stibogluconate P01CC01nifurtimox P01CD01melarsoprol P01CX01pentamidine isethionate P01CX02suramin sodium P01CX03eflornithine P02BA01praziquantel P02BA02oxamniquine P02BX04triclabendazole P02CB02diethylcarbamazine P02CC01pyrantel P02CF01ivermectin P02DA01niclosamide P03AX01benzyl benzoate

RESPIRATORY SYSTEM (R)

FIG. 107 – Summary (graph): Availability of registered products (R) – WHO EML and National EML combined

FIG. 108 – Summary (graph): Availability of registered products (R) – WHO EML and National EML combined

FIG. 109 – Respiratory system (R): Nasal preparations (R01)

FIG. 110 – Respiratory system (R): Throat preparations (R02) and drugs for obstructive airway diseases (R03)

FIG. 111 – Respiratory system (R): Cough and cold preparations (R05)

FIG. 112 – Respiratory system (R): antihistamines for systemic use (R06) and other respiratory system products (R07)

Unavailable WHO EML ATC CodeActive ingredient R03BA01beclometasone R05DA04codeine R06AE03cyclizine

SENSORY ORGANS (S)

FIG. 113 – Summary (graph): Availability of registered products (S) – WHO EML and National EML combined

FIG. 114 – Ophthalmologicals (S01): Antiinfectives (S01A)

FIG. 115 – Ophthalmologicals (S01): Antiinflammatory agents (S01B), Antiinflammatory angents and antiinfectives in combination (S01C), antiglaucoma preparations and miotics (S01E)

FIG. 116 – Ophthalmologicals (S01): Mydriatics and cycloplegics (S01F), decongestants and antiallergics (S01G), local anesthetics (S01H), and diagnostic agents (S01J)

Unavailable WHO EML ATC CodeActive ingredient S01AA09tetracycline S01AA11gentamicin S01BA04prednisolone S01EA01epinephrine S01FA01atropine S01HA03tetracaine

VARIOUS (V)

FIG. 117 – Summary (graph): Availability of registered products (V) – WHO EM List and National EM List combined

FIG. 118 – Various (V): All other therapeutic products (V03)

FIG. 119 – Various (V): Diagnostic agents (V04), all other non-therapeutic products (V07) and contrast media (V08)

Unavailable WHO EML ATC CodeActive ingredient V03AB03edetates V03AB06thiosulfate V03AB08sodium nitrite V03AB09dimercaprol V03AB31potassium ferric hexacyanoferrate (II) 2H2O (Prussian blue) V03AB34fomepizole V04CF01tuberculin, purified protein derivative (PPD) - BCG V07AVTechnical disinfectants V08AC02iotroxic acid

ARETE-ZOE, as a consultancy, provides solutions to complex problems in the high stakes and high consequence environment of Global Pharmaceuticals, including clinical research, healthcare informatics, and public health. We blend established, Pharma sector methodologies, innovation, and adaptations/transfers from other sectors to identify and resolve consequential practices that pose risk and often result in avoidable patient casualty. However, we are specifically, not a patient advocacy group but believe in optimizing organizational effectiveness and that smart business is agile, competitive and profitable, while intrinsically safe, secure, and resilient. We work within a global context because transnational interests influence national circumstances and choices at point of prescription. ARETE-ZOE, provides full spectrum organizational and operational risk management consultancy. Our published materials provide a glimpse of some aspects of our services to demonstrate both knowledge and ongoing participation within the Pharmaceutical Industry. Our analysis and consultancy includes all channels of misuse, diversion, counterfeiting and illicit exploitation of pharmaceuticals, medical devices, and precursor chemicals. Our advisement is to manufactures, jurisdictional entities, insurers, legislators, litigators, patients, and health care providers. ​ This scope also frequently segues into the nexus of crime and terrorism as significant influencers that undermine sector integrity differentiated from other criminal activity. Obviously, vulnerability assessment, information collection management and intelligence production supporting decision-making for risk reduction and interventions are routinely within the scope of our services as well as design and implementation of operational control measures.